Publication

The Carnitine Shuttle Pathway is Altered in Patients With Neovascular Age-Related Macular Degeneration

Downloadable Content

Persistent URL
Last modified
  • 05/15/2025
Type of Material
Authors
    Sabrina L. Mitchell, Vanderbilt UniversityKaran Uppal, Emory UniversitySamantha M. Williamson, Vanderbilt UniversityKen Liu, Emory UniversityL. Goodwin Burgess, Vanderbilt UniversityViLinh Tran, Emory UniversityAllison C. Umfress, Vanderbilt UniversityKelli L. Jarrell, Vanderbilt UniversityJessica N. Cooke Bailey, Case Western Reserve UniversityAnita Agarwal, Vanderbilt UniversityMargaret Pericak-Vance, University of MiamiJonathan L. Haines, Case Western Reserve UniversityWilliam K. Scott, University of MiamiDean Jones, Emory UniversityMilam A. Brantley Jr., Vanderbilt University
Language
  • English
Date
  • 2018-10-01
Publisher
  • Association for Research in Vision and Ophthalmology (ARVO)
Publication Version
Copyright Statement
  • © 2018 The Authors.
License
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0146-0404
Volume
  • 59
Issue
  • 12
Start Page
  • 4978
End Page
  • 4985
Grant/Funding Information
  • Supported by National Institutes of Health (NIH; Bethesda, MD, USA) Grants R01 EY22618 (MAB) and R01 EY012118 (MP-V, JLH, WKS, and AA) and an unrestricted departmental award from Research to Prevent Blindness, and by the Clinical and Translational Science Collaborative of Cleveland, KL2TR000440 from the National Center for Advancing Translational 419 Sciences (NCATS) component of the NIH and NIH roadmap for Medical Research (JNCB).
Supplemental Material (URL)
Abstract
  • PURPOSE. To identify metabolites and metabolic pathways altered in neovascular age-related macular degeneration (NVAMD). METHODS. We performed metabolomics analysis using high-resolution C18 liquid chromatography-mass spectrometry on plasma samples from 100 NVAMD patients and 192 controls. Data for mass/charge ratio ranging from 85 to 850 were captured, and metabolic features were extracted using xMSanalyzer. Nested feature selection was used to identify metabolites that discriminated between NVAMD patients and controls. Pathway analysis was performed with Mummichog 2.0. Hierarchical clustering was used to examine the relationship between the discriminating metabolites and NVAMD patients and controls. RESULTS. Of the 10,917 metabolic features analyzed, a set of 159 was identified that distinguished NVAMD patients from controls (area under the curve of 0.83). Of these features, 39 were annotated with confidence and included multiple carnitine metabolites. Pathway analysis revealed that the carnitine shuttle pathway was significantly altered in NVAMD patients (P = 0.0001). Tandem mass spectrometry confirmed the molecular identity of five carnitine shuttle pathway acylcarnitine intermediates that were increased in NVAMD patients. Hierarchical cluster analysis revealed that 51% of the NVAMD patients had similar metabolic profiles, whereas the remaining 49% displayed greater variability in their metabolic profiles. CONCLUSIONS. Multiple long-chain acylcarnitines that are part of the carnitine shuttle pathway were significantly increased in NVAMD patients compared to controls, suggesting that fatty acid metabolism may be involved in NVAMD pathophysiology. Cluster analysis suggested that clinically indistinguishable NVAMD patients can be separated into distinct subgroups based on metabolic profiles.
Author Notes
  • Milam A. Brantley Jr, Vanderbilt Eye Institute, Vanderbilt University Medical Center, 2311 Pierce Avenue, Nashville, TN 37232-8808, USA; milam.brantley@vumc.org.
Keywords
Research Categories
  • Health Sciences, General

Tools

Relations

In Collection:

Items